{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:14Z","timestamp":1792979894887,"version":"4.5.0"},"reference-count":90,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["177747"],"award-info":[{"award-number":["177747"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019186","name":"HORIZON EUROPE Innovative Europe","doi-asserted-by":"publisher","award":["101015736"],"award-info":[{"award-number":["101015736"]}],"id":[{"id":"10.13039\/100019186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate whether remdesivir is associated with cardiac adverse events (CAEs), addressing concerns raised by basic experiments, clinical case reports and observational studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Systematic review and meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>MEDLINE and Embase, searched from January 2020 to December 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study selection<\/jats:title>\n                  <jats:p>Randomised controlled trials (RCTs) comparing remdesivir with placebo or standard care in patients with COVID-19, with a primary focus on cardiac safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                  <jats:p>We included RCTs that evaluated the safety of remdesivir in patients with COVID-19 . Eligible studies were those that compared remdesivir with placebo or standard care in adult patientsCOVID-19 . Inclusion criteria emphasised safety outcomes, particularly CAEs, as primary endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data extraction and synthesis<\/jats:title>\n                  <jats:p>Two reviewers independently extracted data. Reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Harms guidelines. Risk of bias (RoB) was assessed using the Cochrane Collaboration tool. A random-effects model was used for data synthesis. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was applied to assess the certainty of evidence. The primary outcome was the incidence of any CAEs, defined as a composite of all reported cardiac-related harms. Secondary outcomes included specific CAEs such as arrhythmias, heart failure and myocardial disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 1698 studies, of which seven RCTs met the inclusion criteria, comprising a total of 4566 participants. The RoB was assessed across multiple domains, with four RCTs showing low risk and three showing moderate risk in specific areas. Pooled analysis revealed no significant association between remdesivir use and CAEs (RR=0.84, 95%\u2009CI: 0.68 to 1.04, p=0.118). Subgroup analyses showed consistent findings across different patient demographics and comorbidities. GRADE assessment indicated moderate certainty for overall CAEs, low certainty for arrhythmias and heart failure (due to imprecision and study-level bias), and very low certainty for myocardial disorders (due to small sample size and indirectness).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Contrary to preliminary concerns and case reports, our meta-analysis found no evidence of a statistically significant association between remdesivir and CAEs among patients with COVID-19 . These findings provide reassurance to clinicians regarding the safety profile of remdesivir in this patient population, supporting its use as an antiviral therapy in the treatment of COVID-19. Further research is warranted to validate these findings and to clarify whether remdesivir may have a neutral or potentially protective effect on cardiac outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42022383647.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-089977","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:05:15Z","timestamp":1752833115000},"page":"e089977","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04315948","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-4494","authenticated-orcid":false,"given":"Chengliang","family":"Yang","sequence":"first","affiliation":[{"name":"Prevention of Organ Failure (PROOF) Centre of Excellence,Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-434X","authenticated-orcid":false,"given":"Linda","family":"Lapp","sequence":"additional","affiliation":[{"name":"Prevention of Organ Failure (PROOF) Centre of Excellence,Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-993X","authenticated-orcid":false,"given":"Alain","family":"Amstutz","sequence":"additional","affiliation":[{"name":"CLEAR Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University of Basel, Basel, Switzerland"},{"name":"Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway"},{"name":"Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-5230","authenticated-orcid":false,"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[{"name":"CLEAR Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey P.","family":"Shannon","sequence":"additional","affiliation":[{"name":"Prevention of Organ Failure (PROOF) Centre of Excellence,Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Espin","sequence":"additional","affiliation":[{"name":"Prevention of Organ Failure (PROOF) Centre of Excellence,Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Assadian","sequence":"additional","affiliation":[{"name":"Prevention of Organ Failure (PROOF) Centre of Excellence,Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Toma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7908-1581","authenticated-orcid":false,"given":"Scott J.","family":"Tebbutt","sequence":"additional","affiliation":[{"name":"Prevention of Organ Failure (PROOF) Centre of Excellence,Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025071803050861000_15.7.e089977.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2032369"},{"key":"2025071803050861000_15.7.e089977.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"2025071803050861000_15.7.e089977.3","unstructured":"Centers for Disease Control and Prevention . COVID-19 Treatments and Medications, 2024. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/your-health\/treatments-for-severe-illness.html"},{"key":"2025071803050861000_15.7.e089977.4","unstructured":"Infectious Diseases Society of America . IDSA Guidelines on the Treatment and Management of Patients with COVID-19, 2024. Available: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management"},{"key":"2025071803050861000_15.7.e089977.5","unstructured":"World Health Organization . Remdesivir for COVID-19, 2024. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Therapeutics-Remdesivir-Poster_A-2022.1"},{"key":"2025071803050861000_15.7.e089977.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"2025071803050861000_15.7.e089977.7","unstructured":"National Institute for Health and Care Excellence . COVID-19 rapid guideline: Managing COVID 19, 2024. Available: https:\/\/www.nice.org.uk\/guidance\/ng191\/chapter\/4-Therapeutics-for-COVID-19"},{"key":"2025071803050861000_15.7.e089977.8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1106044","article-title":"Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study","volume":"14","author":"Alsowaida","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025071803050861000_15.7.e089977.9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/cts.13168","article-title":"Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database","volume":"15","author":"Jung","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2025071803050861000_15.7.e089977.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55815","article-title":"Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project","volume":"6","author":"Devgun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025071803050861000_15.7.e089977.11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40261-022-01187-x","article-title":"Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study","volume":"42","author":"Schreiber","year":"2022","journal-title":"Clin Drug Investig"},{"key":"2025071803050861000_15.7.e089977.12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12012-021-09703-9","article-title":"Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review","volume":"22","author":"Nabati","year":"2022","journal-title":"Cardiovasc Toxicol"},{"key":"2025071803050861000_15.7.e089977.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025071803050861000_15.7.e089977.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104955","article-title":"Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes","volume":"184","author":"Choi","year":"2020","journal-title":"Antiviral Res"},{"key":"2025071803050861000_15.7.e089977.15","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00204-022-03306-1","article-title":"The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro","volume":"96","author":"Merches","year":"2022","journal-title":"Arch Toxicol"},{"key":"2025071803050861000_15.7.e089977.16","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/cvr\/cvab311","article-title":"Remdesivir induces persistent mitochondrial and structural damage in human induced pluripotent stem cell-derived cardiomyocytes","volume":"118","author":"Kwok","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2025071803050861000_15.7.e089977.17","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-023-04888-x","article-title":"Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction","volume":"6","author":"Ogawa","year":"2023","journal-title":"Commun Biol"},{"key":"2025071803050861000_15.7.e089977.18","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/cvr\/cvaa267","article-title":"SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes","volume":"116","author":"Bojkova","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2025071803050861000_15.7.e089977.19","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202203388","article-title":"Investigating and Resolving Cardiotoxicity Induced by COVID\u201019 Treatments using Human Pluripotent Stem Cell\u2010Derived Cardiomyocytes and Engineered Heart Tissues","volume":"9","author":"Xu","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"2025071803050861000_15.7.e089977.20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1107198","article-title":"Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study","volume":"13","author":"Hajimoradi","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025071803050861000_15.7.e089977.21","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070611","article-title":"Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System","volume":"14","author":"Rafaniello","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025071803050861000_15.7.e089977.22","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-245289","article-title":"Remdesivir-associated bradycardia","volume":"14","author":"Ching","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025071803050861000_15.7.e089977.23","article-title":"Cardiac Adverse Events With Remdesivir in COVID-19 Infection","volume":"12","author":"Gupta","year":"2020","journal-title":"Cureus"},{"key":"2025071803050861000_15.7.e089977.24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.121.009811","article-title":"Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study","volume":"14","author":"Attena","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025071803050861000_15.7.e089977.25","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00554.2015"},{"key":"2025071803050861000_15.7.e089977.26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijid.2021.09.036","article-title":"Safety and heart rate changes in Covid-19 patients treated with Remdesivir","volume":"112","author":"Brunetti","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2025071803050861000_15.7.e089977.27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.hrcr.2021.05.004","article-title":"Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease","volume":"7","author":"Jacinto","year":"2021","journal-title":"HeartRhythm Case Rep"},{"key":"2025071803050861000_15.7.e089977.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3656"},{"key":"2025071803050861000_15.7.e089977.29","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.934475","article-title":"Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit"},{"key":"2025071803050861000_15.7.e089977.30","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5195\/jmla.2018.513","article-title":"Covidence and Rayyan","volume":"106","author":"Kellermeyer","year":"2018","journal-title":"Jmla"},{"key":"2025071803050861000_15.7.e089977.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025071803050861000_15.7.e089977.32","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/pds.5155","article-title":"Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults","volume":"29","author":"Nishtala","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025071803050861000_15.7.e089977.33","doi-asserted-by":"crossref","first-page":"815151","DOI":"10.3389\/fphar.2021.815151","article-title":"Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS","volume":"12","author":"He","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025071803050861000_15.7.e089977.34","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions version 6.3 (updated August 2023). 2023."},{"key":"2025071803050861000_15.7.e089977.35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/trstmh\/trad084","article-title":"Impact of lamivudine treatment in late pregnancy on the development of the foetal immune response to hepatitis B virus: a meta-analysis in R with the metafor package","volume":"118","author":"Zhao","year":"2024","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025071803050861000_15.7.e089977.36","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1118\/1.3578606","article-title":"Restricted maximum likelihood estimation of PET neuroreceptor occupancy in the absence of a reference region","volume":"38","author":"Radua","year":"2011","journal-title":"Med Phys"},{"key":"2025071803050861000_15.7.e089977.37","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025071803050861000_15.7.e089977.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275368","article-title":"Four common vitamin D receptor polymorphisms and coronary artery disease susceptibility: A trial sequential analysis","volume":"17","author":"Yan","year":"2022","journal-title":"PLoS One"},{"key":"2025071803050861000_15.7.e089977.39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jrsm.1678","article-title":"Avoiding common mistakes in meta-analysis: Understanding the distinct roles of Q, I-squared, tau-squared, and the prediction interval in reporting heterogeneity","volume":"15","author":"Borenstein","year":"2024","journal-title":"Res Synth Methods"},{"key":"2025071803050861000_15.7.e089977.40","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"2025071803050861000_15.7.e089977.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2025071803050861000_15.7.e089977.42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349"},{"key":"2025071803050861000_15.7.e089977.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0"},{"key":"2025071803050861000_15.7.e089977.44","doi-asserted-by":"publisher","DOI":"10.7326\/M21-0653"},{"key":"2025071803050861000_15.7.e089977.45","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.211698"},{"key":"2025071803050861000_15.7.e089977.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"2025071803050861000_15.7.e089977.47","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1093\/ofid\/ofaa439.755","article-title":"Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19","volume":"561","author":"Criner","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025071803050861000_15.7.e089977.48","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1093\/ofid\/ofab466.1642","article-title":"LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"8","author":"Hill","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025071803050861000_15.7.e089977.49","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1093\/ofid\/ofaa439.382","article-title":"72. Remdesivir vs Standard Care in Patients with Moderate covid-19","volume":"7","author":"Marty","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025071803050861000_15.7.e089977.50","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_149_21"},{"key":"2025071803050861000_15.7.e089977.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00519-0"},{"key":"2025071803050861000_15.7.e089977.52","first-page":"886","article-title":"RETRACTED: Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial","volume":"106","author":"Abd-Elsalam","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2025071803050861000_15.7.e089977.53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/2211352520666220517092803","article-title":"Comparison of Efficacy of Remdesivir with Supportive Care Alone in the Treatment of Critically Sick Adult and Child COVID-19 Patients: A Randomized Clinical Trial","volume":"21","author":"Hormati","year":"2023","journal-title":"AIA"},{"key":"2025071803050861000_15.7.e089977.54","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/infdis\/jiad275","article-title":"Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)","volume":"228","author":"Jittamala","year":"2023","journal-title":"J Infect Dis"},{"key":"2025071803050861000_15.7.e089977.55","doi-asserted-by":"crossref","first-page":"100200","DOI":"10.1016\/j.clinsp.2023.100200","article-title":"Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Shams","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"2025071803050861000_15.7.e089977.56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(22)00528-8","article-title":"Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"11","author":"Amstutz","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025071803050861000_15.7.e089977.57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048502","article-title":"Adverse effects of remdesivir, hydroxychloroquine and lopinavir\/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials","volume":"12","author":"Izcovich","year":"2022","journal-title":"BMJ Open"},{"key":"2025071803050861000_15.7.e089977.58","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/23744235.2021.1923799","article-title":"Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"53","author":"Okoli","year":"2021","journal-title":"Infect Dis (Lond)"},{"key":"2025071803050861000_15.7.e089977.59","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/jac\/dkab093","article-title":"Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials","volume":"76","author":"Lai","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025071803050861000_15.7.e089977.60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amsu.2020.12.051","article-title":"Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Reddy Vegivinti","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"2025071803050861000_15.7.e089977.61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106272","article-title":"Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Al-Abdouh","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"2025071803050861000_15.7.e089977.62","article-title":"Remdesivir for the treatment of COVID-19","volume":"1","author":"Grundeis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2025071803050861000_15.7.e089977.63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01689-3"},{"key":"2025071803050861000_15.7.e089977.64","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/cvr\/cvac195","article-title":"Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank","volume":"119","author":"Wan","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025071803050861000_15.7.e089977.65","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41374-022-00783-x","article-title":"Characterization of COVID-19-associated cardiac injury: evidence for a multifactorial disease in an autopsy cohort","volume":"102","author":"Hanson","year":"2022","journal-title":"Lab Invest"},{"key":"2025071803050861000_15.7.e089977.66","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamacardio.2020.3551","article-title":"Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases","volume":"5","author":"Lindner","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025071803050861000_15.7.e089977.67","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa664"},{"key":"2025071803050861000_15.7.e089977.68","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.cmi.2022.03.021","article-title":"COVID-19\u2013Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review","volume":"28","author":"Almamlouk","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025071803050861000_15.7.e089977.69","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","article-title":"SARS-CoV-2 infection and persistence in the human body and brain at autopsy","volume":"612","author":"Stein","year":"2022","journal-title":"Nature New Biol"},{"key":"2025071803050861000_15.7.e089977.70","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"2025071803050861000_15.7.e089977.71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"2025071803050861000_15.7.e089977.72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104552","article-title":"Cellular and molecular biomarkers of long COVID: a scoping review","volume":"91","author":"Esp\u00edn","year":"2023","journal-title":"EBioMedicine"},{"key":"2025071803050861000_15.7.e089977.73","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100612","article-title":"Long COVID: the next public health crisis is already on its way","volume":"28","author":"Yang","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2025071803050861000_15.7.e089977.74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S2213-2600(23)00142-X","article-title":"Association of SARS-CoV-2 infection and persistence with long COVID","volume":"11","author":"Yang","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025071803050861000_15.7.e089977.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01661-4"},{"key":"2025071803050861000_15.7.e089977.76","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/qjmed\/hcab297","article-title":"Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?","volume":"114","author":"Boglione","year":"2022","journal-title":"QJM"},{"key":"2025071803050861000_15.7.e089977.77","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12124158","article-title":"Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19","volume":"12","author":"Badenes Bonet","year":"2023","journal-title":"J Clin Med"},{"key":"2025071803050861000_15.7.e089977.78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s15010-023-02154-0","article-title":"Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review","volume":"52","author":"Fern\u00e1ndez-de-Las-Pe\u00f1as","year":"2024","journal-title":"Infection"},{"key":"2025071803050861000_15.7.e089977.79","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33825-5","article-title":"Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial","volume":"13","author":"Nevalainen","year":"2022","journal-title":"Nat Commun"},{"key":"2025071803050861000_15.7.e089977.80","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00570-1"},{"key":"2025071803050861000_15.7.e089977.81","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1038\/s41401-022-00895-6","article-title":"Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects","volume":"43","author":"Qian","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2025071803050861000_15.7.e089977.82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208822"},{"key":"2025071803050861000_15.7.e089977.83","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00577-7"},{"key":"2025071803050861000_15.7.e089977.84","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40228-7","article-title":"Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants","volume":"14","author":"de Melo","year":"2023","journal-title":"Nat Commun"},{"key":"2025071803050861000_15.7.e089977.85","doi-asserted-by":"crossref","first-page":"1061686","DOI":"10.3389\/fimmu.2022.1061686","article-title":"Omicron variants of SARS-CoV-2 and long COVID","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"2025071803050861000_15.7.e089977.86","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n2943","article-title":"Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear","volume":"375","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"2025071803050861000_15.7.e089977.87","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069445","article-title":"Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review","volume":"378","author":"Pillay","year":"2022","journal-title":"BMJ"},{"key":"2025071803050861000_15.7.e089977.88","unstructured":"Centers for Disease Control and Prevention . Myocarditis and Pericarditis After mRNA COVID-19 Vaccination, 2024. Available: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/myocarditis.html"},{"key":"2025071803050861000_15.7.e089977.89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.5588\/ijtld.21.0282","article-title":"Inhaled remdesivir treatment for COVID-19","volume":"25","author":"Yang","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025071803050861000_15.7.e089977.90","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/cts.13627","article-title":"Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants","volume":"16","author":"Humeniuk","year":"2023","journal-title":"Clin Transl Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-089977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:05:25Z","timestamp":1752833125000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-089977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-089977"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-089977","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}